Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07226791 · ClinicalTrials.gov registry record · Phase 2

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair

A Phase 2 study of Ventral Hernia, sponsored by AbbVie.

Recruiting
Registry status
Phase 2
Development phase
200
Enrollment target
2
Study locations

NCT07226791 is a Phase 2 study of Ventral Hernia that is actively recruiting participants, run by AbbVie. The registered enrollment target is 200 participants, above the 132-participant average among 18 other Ventral Hernia trials with a reported enrollment target (52% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07226791, a Phase 2 study of Ventral Hernia, is actively recruiting participants, sponsored by AbbVie.

RECRUITING
Registry status
Phase 2
Development phase
200 participants
Enrollment target
2
Study locations

Study Summary

A ventral hernia happens when the muscles in the front of your belly become weak and let organs push through, causing a bulge. If it gets worse, intestines can slip into the bulge, leading to serious pain and health problems. This study aims to asses if AGN-151607-DP is safe and effective for closing the belly wall after open ventral hernia surgery, without needing a complex procedure. Adverse Events and change in disease activity will be assessed. AGN-151607-DP is an investigational drug being developed to treat ventral hernia. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 200 adult participants with midline ventral hernia needing open surgical repair will be enrolled in approximately 30 sites in the United States. Participants will receive intramuscular injections of AGN-161607-DP or matching placebo on Day 1. Duration of the study is approximately 25 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions Studied

Ventral Hernia

Interventions

  • DRUG AGN-151607-DP
  • DRUG Placebo for AGN-151607-DP

Study Locations (2)

Florida

  • Medical Research Center /ID# 278680 - Miami

Wisconsin

  • NextStage Clinical Research-Evergreen Surgical /ID# 278710 - Eau Claire

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2026-02-04
Est. Completion 2030-05
Phase Phase 2

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07226791

The ClinicalTrials.gov registry entry for NCT07226791 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 132-participant average among 18 other Ventral Hernia trials with a reported enrollment target (52% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Ventral Hernia appearing as the primary indexed condition, and to 2 interventions - of which AGN-151607-DP is the first listed.

NCT07226791 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Wisconsin.

Frequently Asked Questions

What is clinical trial NCT07226791 about?

NCT07226791 is a clinical study titled "Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair". A ventral hernia happens when the muscles in the front of your belly become weak and let organs push through, causing a bulge. If it gets worse, intestines can slip into the bulge, leading to serious pain and health problems. This study aims to asses if AGN-151607-DP is safe and effective for closin...

What is the current status of trial NCT07226791?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2026-02-04. Estimated completion is 2030-05.

What conditions does trial NCT07226791 study?

This clinical trial studies the following conditions: Ventral Hernia.

What interventions are being tested in trial NCT07226791?

The interventions under investigation include: AGN-151607-DP (DRUG), Placebo for AGN-151607-DP (DRUG).

Who is sponsoring clinical trial NCT07226791?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07226791 being conducted?

This trial has 2 study locations across Florida, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ventral Hernia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ventral Hernia

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.